Mesoblast (ASX:MSB) Insider Lynette Cobley Purchases 30,000 Shares

Mesoblast Limited (ASX:MSB) insider Lynette Cobley bought 30,000 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The stock was acquired at an average cost of A$3.20 per share, with a total value of A$96,000.00.

Mesoblast Price Performance

The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of -23.29, a price-to-earnings-growth ratio of 9.56 and a beta of 2.38. The company has a current ratio of 1.18, a quick ratio of 1.82 and a debt-to-equity ratio of 24.76.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.